Table 6. Summary of reports on hypocellular acute myeloid leukemia.
| Our study | Al-Kali [9] | Naseem S [10] | Nagai K [6] | |
|---|---|---|---|---|
| Reference time period | 2003-2013 | 2000-2009 | 2012-2013 | Before 1992 |
| No. of patients, hAML/all AML | 43/541 | 123/1342 | 8/316 | 32 |
| Age, y (range) | 56 (20-65) | 65 (19,88) | 44 (16-50) | 67 (44,75) |
| Female, % | 21 (48.8) | NA | 3 (37.5) | 9 (28.1) |
| AHD, N (%) | 10 (23.3) | 41 (33.3) | 4 (50) | N.A. |
| WBC count, ×109/L (range) | 2.2 (0.2-64.4) | 1.7 (0.2,64.4) | 2.65 (1.5,4) | 1.45 (0.55, 4.5) |
| HGB level, g/L (range) | 83 (30-142) | 87 (30,142) | 76 (48,111) | 81 (38, 132) |
| PLT count, ×109/L (range) | 51 (4-306) | 57 (4,306) | 42.5 (5,391) | 52.5 (1.5, 262.5) |
| BM cellularity, % (range) | 14 (11-20) | 15 (4-20) | ≤ 40% | 29.8 (12.4-39.8) |
| Induction regimen | “XA” HAG | IDA Clofarabine ± AraC | NA | LD-AraC |
| CR rate, % | 62.8 | 53.7 | NA | 65 |
| Overall survival | 9 months | 38 weeks | NA | NA |
| Event/disease-free Survival | 8 months | 13 weeks | NA | NA |
hAML, Hypocellular acute myeloid leukemia; AHD, anterior hematological disease; CR, complete remission